Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/S-40503> ?p ?o }
Showing triples 1 to 76 of
76
with 100 triples per page.
- S-40503 abstract "S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids.S-40503 is a SARM that shows good functional selectivity for bone tissue, and has relatively little effect on muscle mass and no observable effect on the prostate gland. In animal studies it was shown to increase both bone mineral density and biomechanical strength of femoral cortical bone, and at low doses showed anabolic effects only on bone tissue, while at higher doses both bone and muscle growth were affected, yet prostate gland enlargement was not seen at any dose tested. The lack of virilizing effects means that S-40503 may even be suitable for use in women, which would be a substantial advantage over existing drugs as women tend to be more likely to suffer from osteoporosis, and are generally contraindicated from taking anabolic steroids due to the risk of side effects such as masculinisation and hirsutism. Since these promising initial studies, no further data about S-40503 has been published by Kaken, and it is thought that rather than being developed for human use itself, S-40503 may be more likely to be used as a lead compound for the development of novel derivatives with similar bone anabolic effects, but longer in vivo half-life and better bioavailability.Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to anabolic steroids but with significantly less side effects. For this reason, SARMs have already been banned by the World Anti-Doping Agency since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed.".
- S-40503 iupacName "2-[4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-yl]-2-methylpropan-1-ol".
- S-40503 pubchem "9879175".
- S-40503 thumbnail S-40503.svg?width=300.
- S-40503 wikiPageID "19951521".
- S-40503 wikiPageLength "5312".
- S-40503 wikiPageOutDegree "16".
- S-40503 wikiPageRevisionID "628622915".
- S-40503 wikiPageWikiLink Anabolic.
- S-40503 wikiPageWikiLink Anabolic_steroid.
- S-40503 wikiPageWikiLink Anabolism.
- S-40503 wikiPageWikiLink Benign_prostatic_hyperplasia.
- S-40503 wikiPageWikiLink Benign_prostatic_hypertrophy.
- S-40503 wikiPageWikiLink Category:Alcohols.
- S-40503 wikiPageWikiLink Category:Hormonal_agents.
- S-40503 wikiPageWikiLink Category:Nitro_compounds.
- S-40503 wikiPageWikiLink Category:Quinolines.
- S-40503 wikiPageWikiLink Functional_selectivity.
- S-40503 wikiPageWikiLink Hirsutism.
- S-40503 wikiPageWikiLink Kaken_Pharmaceuticals.
- S-40503 wikiPageWikiLink Osteoporosis.
- S-40503 wikiPageWikiLink Prostate.
- S-40503 wikiPageWikiLink Prostate_gland.
- S-40503 wikiPageWikiLink Selective_androgen_receptor_modulator.
- S-40503 wikiPageWikiLink Testosterone.
- S-40503 wikiPageWikiLink Virilization.
- S-40503 wikiPageWikiLink Virilizing.
- S-40503 wikiPageWikiLink World_Anti-Doping_Agency.
- S-40503 wikiPageWikiLinkText "S-40503".
- S-40503 c "15".
- S-40503 chemspiderid "8054852".
- S-40503 h "23".
- S-40503 hasPhotoCollection S-40503.
- S-40503 inchi "1".
- S-40503 inchikey "YNYAUBNZRZVNLX-UHFFFAOYAP".
- S-40503 iupacName "2".
- S-40503 legalStatus "Investigational new drug".
- S-40503 molecularWeight "293.361".
- S-40503 n "3".
- S-40503 o "3".
- S-40503 pubchem "9879175".
- S-40503 smiles "O=Nc2cc1CCCNc1cc2".
- S-40503 stdinchi "1".
- S-40503 stdinchikey "YNYAUBNZRZVNLX-UHFFFAOYSA-N".
- S-40503 verifiedrevid "405764731".
- S-40503 wikiPageUsesTemplate Template:Androgenics.
- S-40503 wikiPageUsesTemplate Template:Drugbox.
- S-40503 wikiPageUsesTemplate Template:Reflist.
- S-40503 subject Category:Alcohols.
- S-40503 subject Category:Hormonal_agents.
- S-40503 subject Category:Nitro_compounds.
- S-40503 subject Category:Quinolines.
- S-40503 hypernym Modulator.
- S-40503 type Agent.
- S-40503 type Article.
- S-40503 type ChemicalSubstance.
- S-40503 type Drug.
- S-40503 type Agent.
- S-40503 type Alcohol.
- S-40503 type Article.
- S-40503 type Chemical.
- S-40503 type Heterocycle.
- S-40503 type Preparation.
- S-40503 type ChemicalObject.
- S-40503 type Thing.
- S-40503 type Q8386.
- S-40503 comment "S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis.".
- S-40503 label "S-40503".
- S-40503 sameAs m.04y9vkr.
- S-40503 sameAs S-40503.
- S-40503 sameAs S-40503.
- S-40503 sameAs Q7387039.
- S-40503 sameAs Q7387039.
- S-40503 wasDerivedFrom S-40503?oldid=628622915.
- S-40503 depiction S-40503.svg.
- S-40503 isPrimaryTopicOf S-40503.